ClinicalTrials.gg
CompletedNCT04288895Updated Mar 18, 2022

Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India

A Phase 4 interventional study of Vortioxetine in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed at 24 sites in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-03-18.

Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
28th of 54
400 · median 413
Started
2020
with 2 others
Phase 4
13 of 54
none open now
Registered
48th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 28th largest by enrollment, is one of 3 that started in 2020, is one of 13 in phase 4, and was the 48th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of flexible doses of vortioxetine (5 - 20 mg/day) over a period of 12 weeks in patients with depression in India

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has a Major Depressive Episode (MDE), is diagnosed with Major Depressive Disorder (MDD) according to ® and would benefit from pharmacological treatment with vortioxetine. The current MDE should be confirmed using the Mini International Neuropsychiatric Interview (MINI).
  • The patient has a CGI-S ≥4 at screening.

Exclusion criteria

Exclusion Criteria:

  • The patient has a significant risk of suicide according to investigator's clinical judgment or has made an actual suicide attempt in the period of 6 months prior to screening.
  • The patient previously received vortioxetine.

Other in- and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    flexible-dose

    Drug: Vortioxetine

Interventions

  • 5 - 20 mg/day flexible-dose vortioxetine, tablets, orally

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment-Emergent Adverse Events

    Time frame: From baseline to week 12

Secondary outcomes

  1. Change in Patient Health Questionnaire-9 (PHQ-9) total score

    The PHQ-9 is a patient-rated scale designed to screen for and assess depression. The PHQ-9 consists of questions on each of the 9 DSM-5® criteria for depression asking if they have bothered the patient over the last 2 weeks. Each question is rated on a scale from 0 (not at all) to 3 (nearly every day). The 9 questions are summed to a total score ranging from 0 to 27 with higher scores reflecting greater severity.

    Time frame: From baseline to week 12

  2. Change in Clinical Global Impression-severity of illness (CGI-S) score

    The CGI was developed to provide global measures of the severity of a patient's clinical condition and improvement or worsening during clinical studies. The CGI consists of two clinician-rated subscales: severity of illness (CGI-S) and global improvement (CGI-I). The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

    Time frame: From baseline to week 12

  3. Clinical Global Impression-improvement (CGI-I)

    The CGI was developed to provide global measures of the severity of a patient's clinical condition and improvement or worsening during clinical studies. The CGI consists of two clinician-rated subscales: severity of illness (CGI-S) and global improvement (CGI-I). The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: At week 12

07

Study locations

24 sites
  • Ratandeep Multispecialty Hospital (IN1002)
    Ahmedabad, Gujarat 380008, India
  • MITR Foundation 1 (IN1013)
    Ahmedabad, Gujarat 380013, India
  • BJ Medical College and Civil Hospital (IN028)
    Ahmedabad, Gujarat 380016, India
  • Shree Hatkesh Health Foundation (IN1016)
    Junagadh, Gujarat 362001, India
  • Nagecha Hospital, Creative Chamber (IN1015)
    Rajkot, Gujarat 360001, India
  • Divyam Clinic (IN1025)
    Surat, Gujarat 395001, India
  • GMERS Medical College and Hospital,Department of Psychiatry (IN1004)
    Vadodara, Gujarat 390021, India
  • People Tree Hospitals (IN1027)
    Bengaluru, Karnataka 560 022, India
  • Vinaya Hospital & Research Centre (IN1007)
    Mangalore, Karnataka 575 003, India
  • Mangala Hospital & Mangala Kidney Foundation (IN1006)
    Mangalore, Karnataka 575003, India
  • K. S. Hegde Medical Academy (IN1003)
    Mangalore, Karnataka 575018, India
  • Department of Psychiatry K R Hospital Mysore Medical College and Research Institute (IN1020)
    Mysuru, Karnataka 570001, India
  • IQRAA International Hospital & Research Centre (IN030)
    Kozhikode, Kerala 673009, India
  • Society for Psychiatric Update and Research, Shanti Nursing Home (IN1008)
    Aurangabad, Maharashtra 431005, India
  • Arneja Heart and Multispeciality Hospital (IN1022)
    Nagpur, Maharashtra 440010, India
  • Central Institute of Behavioural Sciences (IN1019)
    Nagpur, Maharashtra 440010, India
  • Chopda Medicare & Research Centre (IN023)
    Nashik, Maharashtra 422005, India
  • Lata Mangeshkar Medical Foundation's (IN1001)
    Pune, Maharashtra 411004, India
  • Oyster and Pearl Hospital (IN1014)
    Pune, Maharashtra 411005, India
  • Dayanand Medical College and Hospital (IN024)
    Ludhiana, Punjab 141001, India
  • ASHA hospital (IN1018)
    Hyderabad, Telangana 500034, India
  • Deva Institute of Healthcare and Research PVT ltd. (IN1005)
    Varanasi, Uttar Pradesh 221005, India
  • Institute of Post Graduate Medical Education and Research (IN1026)
    Kolkata, West Bengal 700020, India
  • Maharaja Agarsen Hospital (IN1021)
    Delhi, 110026, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Feb 2022, 23 months.

Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2020
First posted
Feb 28, 2020
StartActual
Feb 20, 2020
Primary completionActual
Feb 11, 2022
CompletionActual
Mar 12, 2022
Last update
Mar 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04288895
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Feb 28, 2020
Start date
Feb 20, 2020
Primary completion
Feb 11, 2022
Completion
Mar 12, 2022
Last update
Mar 18, 2022

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion